Fundraising FoxAntegrin Therapeutics
St. Louis, US · Founded 2014 · Delaware corporation · 1 known investors
Find your way into Antegrin Therapeutics
Sign up to see every warm intro you have to Antegrin Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Antegrin Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
GH
George H. Capps, IIExecutive
RK
Robert KarrExecutive
DW
David W. GriggsNamed on SEC filing
TP
Thomas P. CirritoNamed on SEC filing
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$9.7M disclosed across 3 rounds · 2014–2017
▶$9MraisedAug 2017 · 6 investors · PharmaceuticalsRule 506(c)
▶$9MraisedAug 2017 · 6 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Bradford WilliamsonExecutive Officer
- Ben AuspitzDirector
- Scott SeiwertExecutive Officer
- Peter BarrettDirector
- George H. Capps IIExecutive Officer, Promoter
- Rajesh DevrajDirector
- Offering amount
- $26M
- Amount sold
- $9M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06c
▶$100KraisedOct 2015 · 1 investors · PharmaceuticalsRule 506(c)
▶$100KraisedOct 2015 · 1 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Charles BoltenDirector
- George H. Capps, IIExecutive Officer
- Robert KarrExecutive Officer, Director
- Michael A. YeadonDirector
- David W. GriggsDirector
- Thomas P. CirritoDirector
- Rajesh DevrajDirector
- Offering amount
- $600K
- Amount sold
- $100K
- Minimum investment
- $1
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06c
▶$595.6KraisedOct 2015 · 5 investors · PharmaceuticalsRule 506(b)
▶$595.6KraisedOct 2015 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- George H. Capps, IIExecutive Officer
- David W. GriggsDirector
- Robert KarrExecutive Officer, Director
- Rajesh DevrajDirector
- Charles BoltenDirector
- Thomas P. CirritoDirector
- Michael YeadonDirector
- Offering amount
- $595.6K
- Amount sold
- $595.6K
- Minimum investment
- $1
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Antegrin Therapeutics's investors?
- Antegrin Therapeutics's investors include Atlas Venture.
- How much funding has Antegrin Therapeutics raised?
- Antegrin Therapeutics has disclosed $9.7M raised across 3 rounds.
- Where is Antegrin Therapeutics headquartered?
- Antegrin Therapeutics is headquartered in St. Louis, US.